Enjoy complimentary customisation on priority with our Enterprise License!
Technavio’s market research analyst has estimated the global market for liver diseases therapeutics to grow rapidly during the forecast period. Factors like the increased prevalence of liver cancer in developed countries and the expected entry of pipeline drugs into the market are expected to result in this market’s impressive CAGR of more than 15% by 2019.
The high-unmet medical need of the populace is a key driver for the growth of this market. Drugs that are currently available in this market have adverse side effects and, therefore, results in increased noncompliance among individuals with liver diseases. Additionally, since the availability of hepatitis vaccine is low in many regions, the medical needs of the populace remains unmet for extended periods of time.
This market is highly competitive due to the presence of numerous vendors who have develop branded, generic, and off-label drugs to cure liver diseases. Competition in this market is expected to increase during the forecast period due to the launch of pipeline drugs under different developmental stages.
Key vendors in this market are -
Other prominent vendors are Achillion Pharmaceuticals, AbbVie, Advinus, Angion Biomedica, AstraZeneca, Bayer, BiOrion, Boehringer Ingelheim , Bristol-Myers Squibb, Celsion, Conatus, Digna Biotech, Dynavax Technologies, Eli Lilly, Galectin Therapeutics, Genfit, GenKyoTex, Isis Pharmaceuticals, Janssen Pharmaceuticals, La Jolla Pharmaceutical, LG Life Sciences, Kaketsuken, Mitsubishi Tanabe Pharma, Nitto Denko, Novartis, Onyx Pharmaceuticals (a subsidiary of Amgen), Phenex Pharmaceuticals, Promedior, Promethera Biosciences, ProMetic Life Sciences, Raptor Pharmaceuticals, Shenzhen Kangtai Biological Products, TCM Biotech, Tobira Therapeutics, VBL Therapeutics, Verva Pharmaceuticals, Virobay, and Zafgen.
In this market analysis, Technavio market research analysts have estimated the Hepatitis segment to account for more than 85% of the total market share by 2019. Hepatitis can be of types A, B, C, D, and E, among which hepatitis C is expected to have the highest prevalence during the forecast period. Viral infections, alcoholism, obesity, and diabetes are envisaged to be the most common causes of liver disease.
The Americas are expected to account for the largest market share during the forecast period followed by EMEA and the APAC regions. High medical unmet needs of the populace coupled with the augmented prevalence of liver diseases in the Americas are envisaged to account for its high market share of nearly 49% during the forecast period.
Technavio also offers customization on reports based on specific client requirement.
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Get the report (PDF) sent to your email within minutes.
